Fox Chase Cancer Center (FCCC) has a well-established strategic management planning process and formally produced five-year strategic and financial plans since 1985. These result in rolling five-year recruitment, resource development, and implementation plans which, after review by the Center's External Advisory Board, are approved by the Center Board of Directors. As part of the change in Center leadership during the current CCSG cycle, a comprehensive strategic planning process was launched under the direction of Associate CCSG Director for Academics J. Robert Beck, Wl.D. This is discussed fully in this section of the grant as well as in the """"""""Overall Description of the Cancer Center"""""""" and """"""""Developmental Funds"""""""" sections. The plan incorporates Center mission, vision, and values, as well as 13 Strategic Objectives. Targeted recruitment to each of the five CCSG Research Programs and a balance of individual investigation and team science are Critical Success Factors for the two Discovery Objectives in the Plan. No CCSG funds are requested for this planning effort. CCSG funds are requested for two aspects of our evaluation efforts. First, we seek support for our six external advisory boards, five of which provide review and advice to each of our scientific Programs. The sixth, the President's External Advisory Board, is comprised of national leaders in cancer research and NCI designated Cancer Center directors. These External Advisory Boards have been actively involved in our decisions to reconfigure existing or develop new Shared Facilities. They also provide advice on reconfiguration of existing CCSG Programs as well as the balance of team science and individual investigation. The second request is for partial support for our annual daylong Scientific Retreat where members from all five Programs and our clinical investigators meet and discuss opportunities for translational research as well as a broad-range of cancer-related scientific collaborations.
Strategic planning is a necessary process to ensure future success and growth of cancer research. Evaluation both with internal and via External Advisory Boards is necessary to ensure that goals are achieved in an effective manner.
|Boland, Patrick M; Meyer, Joshua E; Berger, Adam C et al. (2016) Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol :|
|Heckman, Carolyn J; Handorf, Elizabeth A; Darlow, Susan D et al. (2016) An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychol :|
|Meropol, Neal J; Wong, Yu-Ning; Albrecht, Terrance et al. (2016) Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol 34:469-78|
|Hayakawa, K; Formica, A M; Colombo, M J et al. (2016) Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. Leukemia 30:1510-9|
|Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50|
|Duong-Ly, Krisna C; Devarajan, Karthik; Liang, Shuguang et al. (2016) Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep 14:772-81|
|Meeker, Caitlin R; Geynisman, Daniel M; Egleston, Brian L et al. (2016) Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract 12:e755-64|
|Geynisman, Daniel M; Handorf, Elizabeth; Wong, Yu-Ning et al. (2016) Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med 5:192-9|
|Kurimchak, Alison M; Shelton, Claude; Duncan, Kelly E et al. (2016) Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-86|
|Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35|
Showing the most recent 10 out of 884 publications